(Q44848283)

6 December 2017

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients (English)

1 reference

6 December 2017

0 references

0 references

1 reference

1 reference

Priscilla Hollander

1

1 reference

6 December 2017

David G Maggs

2

1 reference

6 December 2017

James A Ruggles

3

1 reference

6 December 2017

Mark Fineman

4

1 reference

6 December 2017

Larry Shen

5

1 reference

6 December 2017

Orville G Kolterman

6

1 reference

6 December 2017

Christian Weyer

7

1 reference

6 December 2017

1 April 2004

1 reference

6 December 2017

1 reference

6 December 2017

12

1 reference

6 December 2017

4

1 reference

6 December 2017

661-668

1 reference

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity

6 December 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Effects of combined insulin-sulfonylurea therapy in type II patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

The prevention and treatment of obesity. Application to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Amylin, food intake, and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Amylin and insulin interact to reduce food intake in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Inhibition of central amylin signaling increases food intake and body adiposity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Behavioral treatment of obesity. Its application to type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

In vitro autoradiographic localization of amylin binding sites in rat brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

Dose-response for glucagonostatic effect of amylin in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2004.76

31 March 2020

Identifiers

DOI

10.1038/OBY.2004.76

1 reference

6 December 2017

1 reference